Cerluten vs Cortexin — Peptide Comparison

Cerluten vs Cortexin — Peptide Comparison Cerluten vs Cortexin — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Cerluten 10–20 mg Cortexin 5–10 mg Frequency Once daily Administration Oral (capsule) Intramuscular (IM) injection Cycle Length 8-12 weeks Onset Speed Gradual (3-4 weeks) Moderate (1-2 weeks) Evidence Level Limited human trials Efficacy Neuroprotection Post-Stroke Recovery Brain Cell Renewal Brain Recovery Cognitive Function Technical Data Molecular Formula C11H17N3O8 (representative primary component) Molecular Weight 319.3 g/mol (representative; complex contains peptides from 200-500 Da) Half-Life Short plasma half-life for individual peptide components (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to gene expression Bioavailability Oral and sublingual absorption via intestinal peptide transporters (PepT1); component peptides cross the blood-brain barrier; sublingual form bypasses first-pass hepatic metabolism CAS Number 75007-24-8 Complex mixture — no single molecular formula (contains multiple low molecular weight polypeptide fractions, L-amino acids, vitamins, and trace elements) Low molecular weight water-soluble polypeptide fractions — specific molecular weight distribution varies as a complex biological mixture Approximately 2-6 hours (varies by route of administration) ~85-100% (intramuscular injection) Not assigned (biological mixture) Protocols standard 1-2 capsules (0.2 g each) 1-2 times daily with meals 30-day intensive course; then 10-day maintenance course every 3 months The common capsule plan used in practice for this CNS peptide supplement. A typical intensive start is 2 capsules daily for 30 days, then 2 capsules daily for 10 days every 3 months. [6] 5-6 drops 3-4 times daily under the tongue 10-30 day course, repeated 2-3 times per year The liquid form is held under the tongue so it absorbs directly. Commonly used at 5-6 drops several times a day. [6] 10 mg 10 days per course; repeat in 3-6 months if needed The standard adult dose per the manufacturer instructions. The 10 mg vial is dissolved in 1-2 mL of saline, water for injection, or 0.5% procaine and injected into a muscle. Children under 20 kg get 0.5 mg/kg. [6] Applications Cognitive recovery following stroke or traumatic brain injury Cerluten is particularly well-suited for individuals focused on cognitive recovery following stroke or traumatic brain injury. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Neuroprotection against age-related cognitive decline and neurodegeneration Cerluten is particularly well-suited for individuals focused on neuroprotection against age-related cognitive decline and neurodegeneration. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Supporting neurogenesis and neuronal repair in aging brain tissue Cerluten is particularly well-suited for individuals focused on supporting neurogenesis and neuronal repair in aging brain tissue. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Comprehensive bioregulatory approach to brain aging using multiple complementary peptide components Cerluten is particularly well-suited for individuals focused on comprehensive bioregulatory approach to brain aging using multiple complementary peptide components. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Cognitive support in chronic cerebral ischemia and cerebrovascular disease Cortexin is particularly well-suited for individuals focused on cognitive support in chronic cerebral ischemia and cerebrovascular disease. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Neuroprotection and neurorecovery following stroke or traumatic brain injury Cortexin is particularly well-suited for individuals focused on neuroprotection and neurorecovery following stroke or traumatic brain injury. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Pediatric neurology including cerebral palsy and developmental delays Cortexin is particularly well-suited for individuals focused on pediatric neurology including cerebral palsy and developmental delays. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Adjunctive treatment in epilepsy management Cortexin is particularly well-suited for individuals focused on adjunctive treatment in epilepsy management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Safety Profile Common Mild headache Mild drowsiness Mild GI discomfort Vivid dreams Uncommon Transient sleep pattern changes Serious No documented serious adverse effects Injection site reactions Headache Dizziness Nausea Agitation or restlessness Transient blood pressure changes Allergic reactions Severe allergic reaction / Anaphylaxis Research Status FDA Status Research compound Safety Overview Cerluten is a peptide extract from cerebral tissue of young animals that is not FDA-approved and lacks rigorous clinical safety data. As an undefined mixture of peptides and proteins from animal sources, quality control and batch consistency cannot be guaranteed. Potential risks include allergic reactions to animal-derived proteins, contamination with microbial pathogens or prions, and unknown long-term immunological effects. No comprehensive safety studies have been conducted in humans, and the active pharmaceutical components have never been identified or standardized. The product exists primarily in Russian and Eastern European medical markets without Western regulatory oversight. Contraindications xKnown hypersensitivity to peptide bioregulators or bovine-derived products xPregnancy and breastfeeding — insufficient reproductive safety data xActive CNS infection — treat infection before initiating peptide bioregulator therapy xPrion disease concerns — although manufacturing processes include purification to remove proteins > 5 kDa, individuals with heightened prion risk should exercise caution Cortexin is a porcine brain-derived polypeptide preparation used in Russian neurology that is not FDA-approved and has no Western rigorous safety data. As an undefined mixture of peptides and proteins extracted from animal brains, batch standardization and quality control are not guaranteed. Concerns include potential transmissible spongiform encephalopathy (TSE/prion) risk from animal CNS tissue, although documented cases have not been reported. Allergic reactions to porcine proteins are possible. No formal human safety assessments, toxicology studies, or clinical trials by modern regulatory standards have been conducted. Use in Western countries is essentially non-existent due to regulatory limitations on animal-derived neurological products. xKnown hypersensitivity to Cortexin or any component including glycine stabilizer xAllergy to bovine-derived biological products xPregnancy — insufficient safety data for use during pregnancy xBreastfeeding — insufficient data on excretion into breast milk Decision Guide Choose Cerluten if... Cognitive recovery following stroke or traumatic brain injury Neuroprotection against age-related cognitive decline and neurodegeneration Supporting neurogenesis and neuronal repair in aging brain tissue Comprehensive bioregulatory approach to brain aging using multiple complementary peptide components Choose Cortexin if... Cognitive support in chronic cerebral ischemia and cerebrovascular disease Neuroprotection and neurorecovery following stroke or traumatic brain injury Pediatric neurology including cerebral palsy and developmental delays Adjunctive treatment in epilepsy management